The efficacy of rituximab in patients with neuromyelitis optica spectrum disorder: A real-world study from Turkey

Author
Uzunkopru, Cihat
ÇİNAR, BİLGE PİRİ
TÜRE, HATİCE SABİHA
Uygunoglu, Ugur
Togrol, Rifat Erdem
TERZİ, MURAT
Kurtuncu, Murat
ÖZAKBAŞ, SERKAN
Tutuncu, Mesude
BECKMANN, YEŞİM
Siva, Aksel
Gunduz, Tuncay
Sen, Sedat
GÜMÜŞ, HALUK
Demir, Serkan
Tutuncu, Melih
Metadata
Show full item record
Abstract
Background Neuromyelitis optica spectrum disorders (NMOSD) are a group of antibody-mediated chronic inflammatory diseases of the central nervous system. Rituximab is a monoclonal antibody that leads to a reduction in disease activity.
URI
http://hdl.handle.net/20.500.12627/170898
https://doi.org/10.1111/ijcp.14158
Collections